We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Landmark Development Agreement Signed Between PDA and St. Petersburg State Chemical-Pharmaceutical Academy

By LabMedica International staff writers
Posted on 26 Jul 2012
The Parenteral Drug Association (PDA; Bethesda, MD, USA) and the Saint-Petersburg State Chemical-Pharmaceutical Academy (SPCPA; St. More...
Petersburg, Russia) have signed a memorandum of understanding to develop a Good Manufacturing Practices (GMP) and Regulatory Affairs Training Center in the area of pharmaceutical manufacturing, an important step in implementing higher standards of quality production in Russia by advancing its pharmaceutical manufacturing technology and quality control.

The Training Center, located in St. Petersburg, will carry out ongoing hands-on training programs for Russian GMP inspectors, SPCPA students, Russian pharmaceutical manufacturers, and professionals of the healthcare industry to improve knowledge and implementation of current GMP. The project will also facilitate the exchange of experience and information on relevant legislation and regulatory procedures. The knowledge gained by students during education in the St. Petersburg Academy will be used to conduct inspections of the pharmaceutical industry in Russia, as measures to help ensure a proper level of quality and efficiency of medical care to meet, as the primary priority, the interests of Russian and guest patients.

This timely project is supported by the government of St. Petersburg and the Ministry of Industry and Trade of the Russian Federation. Richard M. Johnson, PDA President said, "With 600+ pharmaceutical manufacturing plants in Russia it is clear that Russia has made it a priority to enhance understanding and implementing internationally consistent current GMPs. PDA considers this project critical to the overall health of the global pharmaceutical pipeline since there will be more and more of a push for international pharmaceutical companies to partner for manufacturing.” He added, “We are pleased that the SPCPA decided to choose PDA as their premier partner in this significant endeavor.”

Related Links:

Parenteral Drug Association
St. Petersburg State Chemical-Pharmaceutical Academy




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Clinical Informatics Platform
CLARION™
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.